항암항생제 6-Deoxybisanhydrodaunomycinone의 합성

조인호,노영쇠,박시호,안구현,신홍식,한병구,Cho, In Ho,Rho Young Soy,Park, Si Ho,Ahn Koo Hyeon,Sin Hong Sig,Han Byoung Ku 대한화학회 1993 대한화학회지 Vol.37 No.1

항암항생제 Danuorubicin(1b)의 aglycone인 daunomycinone의 전이물질 6-deoxybisanhydrodaunomycinone(20)의 전 합성이 이루어졌다. 만들어진 enone 화합물 4를 phthalide sulfone 7과 반응시킨 뒤 oxidation과 methylation을 시켜서 anthraquinone 화합물 10을 얻었다. 화합물 10의 benzyl기를 bromination시켜서 얻은 monobromo 화합물 11을 bis(tetrabutylammonium) dichromate로 고리화반응을 시켜서 hydroxyanthraquinone 화합물 16을 얻은 뒤 OH기를 thiophenol로 치환시켰다. sulfide 화합물 17은 phosphate buffer 용액속에서 m-CPBA로써 산화시켜서 anthraquinonyl sulfone 화합물 18을 얻은 뒤 methyl vinyl ketone(19)과 결합시켜서 화합물 20을 얻었다. A brief route for total synthesis of 6-deoxybisanhydrodaunomycinone(20) was described, namely the precursor of the daunomycinone, the aglycone of the anticancer antibiotic daunorubicin (1b). The prepared enone 4 was condensed with phthalide sulfone 7 to afford anthraquinone 10 after oxidation and methylation. The benzylic group of 10 was brominated, and subsequent oxidation with bis(tetrabutylammonium) dichromate followed by cyclization give hydroxyanthraquinone 16, which was displaced with thiophenol. Oxidation of 17 with m-CPBA in phosphate buffer solution afforded anthraquinonyl sulfone 18 which was condensed with methyl vinyl ketone (19) to furnish 20.

난소절제로 유도된 골다공증 흰쥐에서 implant 주위 조직 반응에 관한 실험적 연구

조인호,김종여,박수성,박종섭,임헌송,Cho, In-Ho,Kim, Jong-Yeo,Park, Su-Seong,Park, Jong-Sup,Lim, Heon-Song 대한치과보철학회 1998 대한치과보철학회지 Vol.36 No.1

This study was designed to investigate the peri-implant tissue reaction in ovariectomized osteoporotic female rats, and to evaluate effects of estrogen, calcitonin, parathyroid hormone on the bone - implant interface in osteoporotic rats. 120 Sprague - Dawley rats were used in this experiments. Osteoporosis was induced by bilateral ovariectomy. They were divided 5 groups : sham-operated control group(Sham), ovariectomized group (OVX), OVX and estrogen treated group (OVX+E), OVX and PTH treated group (OVX+PTH), and OVX and calcitonin treated group (OVX+CT). Eight weeks after ovariectomy, two titanium screw implants were inserted into the left tibia of each rat. Eight weeks after the insertion of the implants, the periotest values (PTV) of implant were examined, and the rats were sacrificed, and examined the reaction of bone tissue surrounding the implant both histologically and histomorphometrically. The bone density and ash weight of opposite right tibia were examined. Over 40 rats were fractured on left tibia that was implant inserted. On histologically finding, all groups were osseointegrated well, especially in OVX+PTH group. In OVX group, tibial cortical bone showed many large harversian canal and microfracture lines. The OVX+PTH group showed the lowest mean PTV (-2.33) (p<0.05), and the hightest mean bone - implant contact percentage (89%) (p>0.05). But the OVX+CT group showed the highest mean bone density ($5.45mg/cm^3$) and ash weight (56.12%) (p<0.05). The results indicate that PTH treatment enhances osseointegration of implant in OVX rats, and CT treatment depresses bone turnover and prevent the development of osteopenia in OVX rats.

능동형 인덕터 Shuut Peaking을 이용한 0.25 μm CMOS TIA 설계 및 제작

조인호,임영석,Cho In-Ho,Lim Yeongseog 한국전자파학회 2005 한국전자파학회논문지 Vol.16 No.9

본 논문에서는 TSMC 0.25 ${\mu}m$ CMOS RF-Mixed mode 공정 기술을 이용하여 초고속 광통신 시스템의 수신부에 사용되는 광대역 transimpedance amplifier를 설계하였다. 특히 광대역을 구성하기 위해 cascode와 common-source 구조에 active inductor shunt peaking을 이용하여 설계 및 제작하였으며, 측정 결과 gain 변화 없이 -3 dB 대역폭 특성이 cascode는 0.8 GHz에서 $81\%$ 증가한 1.45 GHz, common-source는 0.61 GHz에서 $48\%$ 증가한 0.9 GHz 결과가 나왔으며, 전체 파워 소비는 바이어스 2.5 V를 기준으로 37 mW와 45 mW이며, transimpedance gain은 61 dB$\Omega$과 61.4 dB$\Omega$을 얻을 수 있었다. 그리고 input noise current density도 상용 TIA와 거의 비슷한 $5 pA/\sqrt{Hz}$와 $4.5 pA/\sqrt{Hz}$를 가지며, out put Return loss는 전 대역에서 -10 dB 이하의 정합 특성을 보였다. 그리고 전체 chip 사이즈는 $1150{\times}940{\mu}m^2$이다. This paper presents technique of wideband TIA for optical communication systems using TSMC 0.25 ${\mu}m$ CMOS RF-Mixed mode. In order to improve bandwidth characteristics of an TIA, we use active inductor shunt peaking to cascode and common-source configuration. The result shows the 37 mW and 45 mW power dissipation with 2.5 V bias and 61 dB$\Omega$ and 61.4 dB$\Omega$ transimpedance gain. And the -3 dB bandwidth of the TIA is enhanced from 0.8 GHz to 1.45 GHz in cascode and 0.61 GHz to 0.9 GHz in common-source. And the input noise current density is $5 pA/\sqrt{Hz}$ and $4.5 pA/\sqrt{Hz}$, and -10 dB out put return loss is obtained in 1.45 GHz. The total size of the chip is $1150{\times}940{\mu}m^2$.

새로운 Michael Acceptor를 이용한 Naphthoate 유도체 합성

조인호,노영쇠,이준용,소상문,김성렬,신홍식,유동진,김석인,Cho, In-Ho,Rho, Young-Soy,Lee, Jun-Yong,Soh, Sang-Moon,Kim, Sung-Lyeol,Sin, Hong-Sig,Yoo, Dong-Jin,Kim, Seok-In 대한화학회 1991 대한화학회지 Vol.35 No.6

염증성 치은조직과 치주인대세포에서 Cytokine에 의해 유도되는 열충격단백 발현에 관한 연구

조인호,김덕규,김은철,유형근,신형식,Cho, In-Ho,Kim, Doek-Kyu,Kim, Eun-Cheol,You, Hyung-Keun,Shink, Hyung-Shin 대한치주과학회 1998 Journal of Periodontal & Implant Science Vol.28 No.1

Prokaryotic and eukaryotic cells respond to heat stress and other environmental abuses by synthesizing a small set of stress proteins and by inhibiting post-transcription synthesis of normal proteins. The purpose of the present study was to document the stress response produced by inflamed gingival tissue in vivo, and cytokine inducted human periodontal ligament cells. Human PDL cells were exposed to TNF-$\alpha$(1ng/ml), INF-$\gamma$(200 U/ml), LPS(100ug/ml), combination of cytokine, and SDS-PAGE gels running and Western blotting analysis was done. In vivo studies, the healthy gingival tissusse of a control group and inflamed gingival tissue of adult periodontitis were studied by immunohistochemistry and histology. The results were as follows 1. HSP 47 was distributed on basal layer in healthy gingiva, but stronger stained in basal, suprabasal, and spinous layer of inflamed gingiva. 2. HSP 47 was rare on endothelial cells and mononuclear cells in healthy gingiva, but stronger expressed in inflamed gingiva. 3. HSP 70 expression was rare on epihelium and inflammatory cells hi both healthy & inflamed gingiva. 4. HSP 70 was actively expressed on endothelial cells and inflammatory cells of capillary lumen in moderately & mild inflamend gingiva. 5. PDL cells showed low level of HSP 47 protein expression which was significantly induced by cytokine stimulation (LSP only and combination). 6. Maximum HSP 70 protein induction was seen with stimulation by a combination of the cytokine, Combination of TNF-$\alpha$, INF-$\gamma$, LPS have been shown to synergistically effects of HSP 70 expression. On the above findings, HSP Is influenced by cytokine and chronic inflammation in vivo, and may be involved in protection of tissue during periodontal inflammatiom.

항암항생제 Rhodomycin의 Aglycone인 (${\pm}$)-${\gamma}$-Rhodomycinone과 10-Deoxy-${\gamma}$-rhodomycinone의 합성 (제 2 보)

조인호,정진순,노영쇠,In Ho Cho,Jin Soon Chung,Young S. Rho,Richard P. Rhee 대한화학회 1988 대한화학회지 Vol.32 No.6

항암항생제 Rhodomycin(2)의 합성단계 최종물질인 (${\pm}$)-${\gamma}$-Rhodomycinone(4) 과 10-Deoxy-${\gamma}$-rhodomycinone(5)이 9-ethyl-9,10-epoxy-4,6, 11-trihydroxy-7,8,9,10-tetrahydronaphthacene-5,12-dione(10)의 epoxide ring 쪼개짐으로부터 만들어졌고, epoxide 10은 Hauser-Rhee가 개발한 고리접합법을 이용해서 만든 9-acetyl-4,5,6,11,12-pentamethoxy-7,8-dihydronaphthacene(6)으로 부터 얻었다. $({\pm})-{\gamma}$-Rhodomycinone(4) and 10-Deoxy-${\gamma}$-rhodomycinone(5), late-stage Precursors of the alglycone of antitumor antibiotic Rhodomycin(2) were prepared from the cleavage of epoxide ring of 9-ethyl-9,10-epoxy-4,6, 11-trihydroxy-7,8,9,10-tetrahydronaphthacene-5,12-dione(10). The epoxide 10 was furnished from 9-acetyl-4,5,6,11,12-pentamethoxy-7,8-dihydronaphthacene(6), which was assembled utilizing ring annelation methodology developed by Hauser-Rhee.

연구발표논문초록 ( 공정시스템 (Ⅰ) ) : 다단 증류탑의 최적 설계에 관한 연구

조인호,윤인섭 ( In Ho Cho,En Sup Yoon ) 한국화학공학회 1988 춘계학술발표회 Vol.- No.-

총의치 인상

조인호,Cho, In-Ho 대한치과보철학회 1989 대한치과보철학회지 Vol.27 No.1

9,10-Dideoxy-${\beta}$-rhodomycinone의 합성

조인호,노영쇠,소상문,유동진,이준용,한병구,In Ho Cho,Young Soy Rho,Sang Moon Sho,Dong Jin Yoo,Jun Yong Lee,Byoung Ku Han 대한화학회 1992 대한화학회지 Vol.36 No.6

${\beta}$-rhodomycinone(1)의 전 단계물질인 9,10-dideoxyrhodomycinone(30)의 전 합성이 이루어졌다. Phthalide sulfone 4를 몇 단계의 반응을 진행시켜서 naphthalide sulfone 12로 변형시킨 뒤, 음이온으로 변형된 naphthalide sulfone 12를 5-ethyl-1,3-cyclohexenone(21)과 Michael 부가반응시켜서 선형으로 결합된 tetracyclic 케톤 화합물 26을 좋은 수율로 얻었다. 화합물 26의 케톤기는 sodium borohydride로 환원시키고 메틸기로 보호하여 화합물 28을 얻었다. 9,10-Dideoxy-${\beta}$-rhodomycinone(30)은 pentamethoxy tetracyclic 화합물 28을 oxidative demethylation시키고 메틸기를 제거시켜서 합성하였다. Total synthesis of 9,10-dideoxyrhodomycinone(30) which is the late-stage precursor of naturally occuring ${\beta}$-rhodomycinone(1) is described. After phthalide sulfone 4 was converted to naphthalide sulfone 12 by the several step. Michale addition of naphthalide sulfone 12 which was converted to an anion with 5-ethyl-1,3-cyclohexenone(21) gave a good yield of linearly condensed tetracyclic ketone compound 26. The keto group of 26 was reduced with sodium borohydride and protected by methyl group to afford compound 28. 9,10-Dideoxy-${\beta}$-rhodomycinone(30) was synthesized from pentamethoxy tetracyclic compound 28 by oxidative demethylation and demethylation of 29.

항암항생제 Daunorubicin의 Aglycone, 7,9-Dideoxydaunomycinone의 합성 (제1보)

조인호,이풍래,노영쇠,In Ho Cho,Richard P. Rhee,Young Soy Rho,F. M. Hauser 대한화학회 1986 대한화학회지 Vol.30 No.1

항암항생제 Daunorubicin(2a)합성단계의 최종물질인 7,9-Dideoxydaunomycinone (32)를 3-methoxybenzoic acid(5)로 부터 합성하였다. 3-methoxybenzoic acid를 4-methoxy-3-(phenylsulfonyl)-1(3H)-isobenzofuranone(11)으로 변형시킨 뒤 Hauser와 Rhee가 개발한 고리접합법을 이용하여 trimethoxynaphthoate 16을 얻은 후에 phenylsulfonylnaphthofuranone 22로 변화시킨 뒤 이 물질을 7-(ethylenedioxy)-2-octenoate(23)과 Michael형태의 반응을 전개시켜 anthracenoate 24를 얻었다. Anthracenoate을 tetracyclic 화합물 28로 바꾼뒤 ring B와 C에 붙은 methyl기들을 제거하여 7,9-Dideoxydaunomycinone(32)를 만들었다. 7,9-Dideoxydaunomycinone (32), a late-stage precursor of the aglycone of antitumor antibiotic daunorubicin(2a) was prepared from 3-methoxybenzoic acid(5). Thus, 3-methoxybenzoic acid was converted to 4-methoxy-3-(phenylsulfonyl)-1(3H)-isobenzofuranone(11), which furnished trimethoxynaphthoate 16 upon ring annelation developed by Hauser and Rhee. The trimethoxynaphthoate 16 upon ring annelation developed by Hauser and Rbee. The trimethoxynaphtboate 16 was then transformed into phenylsulfonylnaphthofuranone 22, which was used to make anthracenoate 24 via Michael type reaction with 7-(ethylenedioxy)-2-octenoate(23). Conversion of anthracenoate 24 to tetracyclic product 28, followed by subsequent deprotection of the methyl groups in ring-B and C furnished 7, 9-Dideoxydaunomycinone(32).